List of Excipients in Branded Drug VOTRIENT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	VOTRIENT	pazopanib hydrochloride	0078-0670	CELLULOSE, MICROCRYSTALLINE
Novartis Pharmaceuticals Corporation	VOTRIENT	pazopanib hydrochloride	0078-0670	FERROSOFERRIC OXIDE
Novartis Pharmaceuticals Corporation	VOTRIENT	pazopanib hydrochloride	0078-0670	HYPROMELLOSES
Novartis Pharmaceuticals Corporation	VOTRIENT	pazopanib hydrochloride	0078-0670	MAGNESIUM STEARATE
Novartis Pharmaceuticals Corporation	VOTRIENT	pazopanib hydrochloride	0078-0670	POLYETHYLENE GLYCOL 400
Novartis Pharmaceuticals Corporation	VOTRIENT	pazopanib hydrochloride	0078-0670	POLYSORBATE 80
Novartis Pharmaceuticals Corporation	VOTRIENT	pazopanib hydrochloride	0078-0670	POVIDONE

Votrient Excipient Strategy and Commercial Opportunities for Pazopanib

Last updated: August 23, 2026

Votrient is an oral pazopanib hydrochloride tablet approved for advanced renal cell carcinoma and advanced soft-tissue sarcoma. Its excipient platform is relatively conventional: microcrystalline cellulose, povidone, sodium starch glycolate, magnesium stearate, and a film-coating system. The commercial opportunity is therefore less likely to come from novel excipient ownership and more likely to come from bioequivalent generic development, improved dissolution, food-effect control, patient-centric dosage forms, and manufacturing efficiency.

Pazopanib has formulation risk because it is a poorly soluble, pH-dependent compound with clinically important food and acid-reducing-agent interactions. A successful competitor must control particle size, polymorphic form, wetting, disintegration, dissolution, and tablet compression without creating a clinically meaningful exposure difference. The most attractive opportunities are generic pazopanib tablets, differentiated 505(b)(2) products, excipient-enabled formulation services, and specialty-manufacturing platforms for low-solubility oncology drugs.

What excipients are used in Votrient tablets?

Votrient tablets use a conventional immediate-release solid oral formulation. The FDA labeling identifies the inactive ingredients as:

Formulation function	Votrient excipient	Likely technical role
Diluent and compression aid	Microcrystalline cellulose	Tablet bulk, compactibility, mechanical strength
Binder	Povidone	Granule and tablet cohesion
Disintegrant	Sodium starch glycolate	Tablet breakup and drug release
Lubricant	Magnesium stearate	Ejection from the tablet press
Film coating	Hypromellose-based coating system and colorants	Protection, identification, swallowability, appearance

Votrient is available as 200 mg and 400 mg film-coated tablets. The product is administered orally and is not designed as a modified-release dosage form.[1]

The excipient system is commercially important because it provides a clear reference formulation for generic development. A generic manufacturer does not need to duplicate every excipient at the same concentration, but it must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway. Changes in disintegrant level, lubricant exposure, granulation method, or coating composition can affect dissolution and clinical performance.

Why does pazopanib create formulation challenges?

Pazopanib is a weakly basic, poorly soluble drug with pH-dependent solubility. Its absorption is sensitive to gastrointestinal conditions, including food intake and gastric pH. The FDA label directs patients to take Votrient without food, at least one hour before or two hours after a meal.[1]

The label reports that a high-fat meal approximately doubles exposure and that a low-fat meal also increases exposure compared with administration under fasting conditions. Acid-reducing agents can reduce pazopanib exposure by raising gastric pH. These characteristics create several formulation constraints:

1. The tablet must release pazopanib consistently under physiologically relevant pH conditions.
2. Excipients must not create excessive variability in wetting or precipitation.
3. The formulation must avoid further magnifying the food effect.
4. Dissolution performance must remain stable across manufacturing lots.
5. Tablet hardness and lubrication cannot be optimized at the expense of drug release.

For generic manufacturers, dissolution method development is likely to be a larger technical issue than the selection of an unusual excipient. The central challenge is reproducing the reference product's in vitro release profile across pH conditions while maintaining acceptable stability.

What excipient strategies are most relevant to generic Votrient?

Conventional immediate-release substitution

The lowest-risk strategy is a conventional immediate-release tablet using widely accepted compendial excipients:

• Microcrystalline cellulose or an alternative cellulose-based diluent
• Povidone or copovidone as a binder
• Sodium starch glycolate, croscarmellose sodium, or crospovidone as a disintegrant
• Magnesium stearate or another approved lubricant
• A standard hypromellose film coat

This approach has the shortest regulatory path when the resulting product matches the reference product in strength, dosage form, route, and release characteristics. It also offers the lowest excipient regulatory risk because these materials have extensive use in oral solid dosage forms.

The main commercial limitation is price competition. Once multiple suppliers obtain approval, the product is likely to compete primarily on manufacturing cost, supply reliability, launch timing, and payer access.

Particle engineering and wetting control

Pazopanib's low solubility creates an opportunity for particle-size reduction, improved wetting, or controlled precipitation. Potential approaches include:

• Micronized active pharmaceutical ingredient
• Improved wetting through surfactant selection
• Amorphous or partially amorphous dispersion systems
• Drug-polymer complexes
• Co-milled drug-excipient systems
• Granulation processes that improve drug distribution

These approaches may improve dissolution but can increase regulatory and manufacturing complexity. Amorphous material can recrystallize during storage. Surfactants can affect stability, gastrointestinal tolerability, and dissolution behavior. Milling can change surface energy and create electrostatic handling problems.

A formulation that relies on a novel physical state of pazopanib may create stronger technical differentiation, but the sponsor must establish control of solid-state properties through the chemistry, manufacturing, and controls package.

Disintegrant optimization

The reference product contains sodium starch glycolate. Generic manufacturers may evaluate crospovidone or croscarmellose sodium to improve rapid tablet breakup. The choice affects:

• Disintegration time
• Water uptake
• Granule strength
• Dissolution at different pH values
• Sensitivity to compression force
• Lot-to-lot performance

For a poorly soluble compound, faster disintegration does not automatically produce better dissolution. Excessive swelling can create agglomerates or hinder drug wetting. The most valuable formulation work will link disintegration behavior to discriminatory dissolution data rather than treating disintegration time as a standalone target.

Lubrication and tabletability

Magnesium stearate is a standard lubricant, but over-lubrication can produce hydrophobic tablet surfaces and slow dissolution. The risk is material for pazopanib because dissolution is already constrained by aqueous solubility.

Commercial developers can investigate:

• Lower lubricant concentrations
• Shorter lubrication times
• Alternative lubricants
• Process-controlled blending
• Direct compression versus wet granulation

These changes can reduce batch variability and improve dissolution, but they must be evaluated against tablet ejection force, sticking, capping, hardness, and scale-up behavior.

What commercial opportunities exist beyond a standard generic?

Generic pazopanib tablets

The primary opportunity is a lower-cost generic version of Votrient. Pazopanib is a small molecule, so the relevant pathway is an abbreviated new drug application rather than a biosimilar application. Generic entrants can compete through:

• 200 mg and 400 mg strengths
• Reliable oncology distribution
• Hospital and specialty-pharmacy contracting
• Short lead times for supply
• Lower manufacturing cost
• Dual-source or regional production

The strongest business case is likely to be a manufacturer that already operates high-containment or oncology solid-dose facilities and can use existing packaging, analytical, and quality infrastructure.

505(b)(2) reformulation

A 505(b)(2) product could seek differentiation through a formulation or administration advantage, such as:

• Reduced food-effect variability
• Improved dissolution under elevated gastric pH
• An orally dispersible tablet
• A smaller tablet
• A liquid or multiparticulate dosage form
• A dosing system for patients with swallowing difficulty
• A formulation that reduces dependence on strict meal timing

A 505(b)(2) product would face a higher development burden than an ordinary generic. It would need a persuasive clinical and regulatory rationale, and the commercial advantage must be large enough to offset formulation development, clinical pharmacology, manufacturing, and market-access costs.

Excipient and formulation-platform licensing

The more scalable opportunity may involve licensing formulation technology rather than launching pazopanib itself. Relevant platform assets include:

• Amorphous solid dispersions for weak bases
• Spray-dried dispersion technology
• Nanomilling
• Lipid-based delivery systems
• pH-modifying excipient systems
• Precipitation inhibitors
• High-throughput dissolution screening
• Continuous manufacturing for low-dose, high-value oncology tablets

A platform owner can use pazopanib as a development case while targeting other poorly soluble kinase inhibitors. The commercial value depends on whether the technology improves exposure consistency without requiring a new clinical dosing paradigm.

What patents protect Votrient and its formulation?

Votrient's intellectual-property estate is expected to include multiple categories:

Patent category	Commercial relevance
Pazopanib compound patents	Core composition-of-matter protection
Salt and solid-state patents	Protection for pazopanib hydrochloride or specific solid forms
Pharmaceutical composition patents	Protection for drug-excipient combinations or dosage forms
Method-of-use patents	Protection for renal cell carcinoma, soft-tissue sarcoma, or dosing regimens
Manufacturing patents	Protection for synthesis, purification, crystallization, or solid-state control
Pediatric exclusivity	Time-limited regulatory extension, where granted

The Orange Book is the controlling public source for FDA-listed patents and regulatory exclusivity associated with an approved product.[2] Patent expiration should be reviewed patent by patent because expiration can differ based on patent term adjustment, patent term extension, terminal disclaimers, pediatric exclusivity, and litigation outcomes.

The core NCE exclusivity period for Votrient has expired. FDA approved Votrient in October 2009, so the five-year NCE exclusivity period no longer blocks ANDA submission.[1] The remaining commercial barriers are therefore primarily patent-related, regulatory, technical, and economic.

Are formulation patents the main barrier?

For a conventional immediate-release pazopanib tablet, formulation patents are likely to be less difficult to design around than a valid composition-of-matter patent. A generic developer can potentially use different:

• Binder
• Disintegrant
• Lubricant
• Film-coating composition
• Granulation process
• Particle-size specification
• Manufacturing sequence

A formulation patent becomes more consequential if it claims a narrow dissolution profile, a specific solid form, a defined particle-size distribution, a particular drug-polymer matrix, or a clinically relevant method of reducing food or pH effects.

When does Votrient lose exclusivity?

Votrient lost regulatory NCE exclusivity years after its 2009 approval. Market entry depends on the status of Orange Book-listed patents and any applicable pediatric exclusivity.

The relevant exclusivity timeline is:

Event	Timing
FDA approval of Votrient	October 2009
Five-year NCE exclusivity	Expired in 2014
ANDA submission eligibility	Available after NCE exclusivity, subject to patent certification requirements
Generic launch	Dependent on listed-patent status, Paragraph IV outcomes, settlements, and regulatory approval
Biosimilar pathway	Not applicable because pazopanib is a small molecule

Patent expiry should not be represented as a single Votrient date without reviewing the current Orange Book entries and applicable certificates. A transaction model should distinguish between earliest ANDA filing eligibility, approval eligibility, launch eligibility, and actual market entry.

Which companies are challenging Votrient?

The relevant challengers are generic pharmaceutical companies filing ANDAs for pazopanib tablets. FDA approval announcements, Orange Book entries, and Paragraph IV litigation dockets are the principal sources for identifying named applicants and launch timing.[2,3]

A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable, or not infringed. If the patent holder brings an infringement action within the statutory period, FDA approval may be subject to a litigation stay of up to 30 months, subject to statutory exceptions and court developments.[4]

The practical risk analysis should classify each potential entrant by:

• ANDA filing date
• Paragraph IV or Paragraph III certification
• Strengths covered
• Patent claims challenged
• District-court filing
• 30-month-stay status
• Settlement terms
• Tentative approval
• Final approval
• Commercial launch

A settlement can materially change the entry date even when the challenger has a strong invalidity position. Authorized-generic arrangements, royalty structures, supply agreements, and launch licenses can also alter the expected market-entry economics.

How strong is the Votrient patent estate?

The estate's strength should be assessed by claim type rather than patent count.

Claim type	Relative vulnerability for a generic entrant
Composition of matter	Usually the strongest claim category
Specific salt or crystalline form	Strong if solid-form control is demonstrable and infringement is difficult to avoid
Broad tablet composition	Often more vulnerable to design-around strategies
Narrow dissolution or particle-size claim	Potentially strong if technically necessary for bioequivalence
Method of use	Commercially relevant for indication-specific prescribing, but difficult to enforce against all generic use
Manufacturing process	Stronger when the process is difficult to detect from the finished product

A patent estate with several formulation patents does not automatically prevent generic entry. The key questions are whether the claims cover unavoidable product attributes, whether noninfringing alternatives exist, and whether the claims survive validity challenges.

What manufacturing and excipient barriers affect pazopanib entry?

Manufacturing barriers are moderate rather than biologic-level. Pazopanib does not require sterile filling, cold-chain distribution, or cell-culture capacity. The principal barriers are:

• Active-ingredient sourcing and impurity control
• Particle-size and solid-state consistency
• Safe handling of potent oncology material
• Low-dose content uniformity, depending on tablet composition
• Dissolution reproducibility
• Film-coating uniformity
• Stability under commercial packaging conditions
• Supplier qualification for critical excipients

Excipient supply is unlikely to be a fundamental barrier because the principal excipients are widely available. The higher-value supply opportunity lies in validated, differentiated excipient systems that improve dissolution or process robustness.

How does Votrient compare with other oral kinase inhibitors?

Votrient has a conventional tablet platform but a more difficult biopharmaceutic profile than a highly soluble immediate-release drug. Compared with some oral kinase inhibitors, pazopanib has a particularly important food effect and sensitivity to acid-reducing therapy.[1,5]

Attribute	Votrient	Commercial implication
Dosage form	Immediate-release film-coated tablet	Generic development is technically accessible
Active ingredient	Pazopanib hydrochloride	Salt and solid-state control matter
Solubility	Poor and pH-dependent	Dissolution is a core development risk
Food effect	Clinically significant	Reformulation opportunity exists
Acid-reducing interaction	Clinically relevant	pH-modifying formulations may differentiate
Biologic product	No	Biosimilar competition is irrelevant
Excipient complexity	Moderate	Conventional excipient substitution is feasible
Specialty distribution	Likely important	Supply reliability can support commercial share

What revenue exposure and launch scenarios matter?

The original Votrient franchise generated material oncology revenue for its sponsor, but branded revenue declines as generic competition develops. A commercial model should use three scenarios:

1. Delayed generic entry: Patent litigation or settlement delays competition, preserving a larger branded share for a limited period.
2. Single or limited generic entry: One or a few approved suppliers enter with moderate price erosion and continued specialty-channel economics.
3. Multi-source generic entry: Several manufacturers compete, producing rapid price erosion and lower per-unit margins.

The best opportunity for a generic manufacturer is usually early approval combined with a reliable supply position. For an excipient technology company, the value proposition is stronger when the same platform can be applied across several poorly soluble oncology products rather than only to pazopanib.

Key Takeaways

• Votrient uses a conventional immediate-release tablet excipient system centered on microcrystalline cellulose, povidone, sodium starch glycolate, magnesium stearate, and a film coat.
• Pazopanib's poor, pH-dependent solubility makes dissolution and exposure control the main formulation risks.
• The most practical generic strategy is a conventional bioequivalent tablet with careful control of particle size, lubrication, disintegration, and dissolution.
• The strongest differentiated opportunities involve reducing food-effect variability, improving performance under elevated gastric pH, or creating patient-centric dosage forms.
• Votrient is a small-molecule product, so generic ANDA competition applies; biosimilar competition does not.
• The NCE exclusivity period expired years ago. Patent-specific Orange Book analysis remains central to launch timing.
• Formulation and manufacturing patents are more likely to be designed around than unavoidable composition-of-matter claims.
• Excipient suppliers can capture value through validated low-solubility formulation platforms, not only through commodity excipient sales.
• Revenue exposure depends primarily on the number and timing of generic entrants, launch settlements, and the speed of price erosion.

FAQs

Can a generic Votrient use different excipients?

Yes. A generic pazopanib product generally may use different inactive ingredients if it meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, safety, and labeling.

Could an enteric-coated pazopanib product reduce the food effect?

Possibly, but enteric coating changes the site and timing of release and would require substantial formulation and clinical evaluation. It would not automatically produce bioequivalence or solve pH-related absorption issues.

Is nanocrystalline pazopanib commercially attractive?

It may be attractive where dissolution limits exposure or creates high variability. The technology must demonstrate physical stability, scalable manufacture, and a meaningful regulatory or clinical advantage.

Are standard excipients subject to patent risk in a pazopanib generic?

Standard excipients are generally available from multiple suppliers, but a specific combination, concentration range, processing method, or dissolution profile may be claimed in a patent. Freedom-to-operate analysis must examine the full formulation and manufacturing process.

Can a pazopanib formulation qualify for a new period of market exclusivity?

A reformulated product may qualify for regulatory exclusivity only if it meets the applicable statutory requirements and receives approval through a qualifying pathway. A formulation change alone does not guarantee new exclusivity.

References

1. U.S. Food and Drug Administration. (2009). Votrient (pazopanib hydrochloride) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
4. U.S. Code, 21 U.S.C. § 355(j). (2024). Abbreviated applications for new drugs.
5. European Medicines Agency. (2010). Votrient: EPAR - product information.